CATX (Perspective Therapeutics, Inc.) Market Value to Book Value Ratio

This daily price chart for Perspective Therapeutics (CATX) on the GURU.Markets platform reflects the price action of an asset currently valued at 0.42. Perspective Therapeutics develops high-precision alpha-particle radiopharmaceuticals to combat tumors. Antibody patents and the complexity of isotope handling protect the business from competitors, while a proprietary air transport network ensures the rapid delivery of short-lived substances.

The selection of defensive assets is based on comparing the real cost of capital with market expectations. For Perspective Therapeutics (CATX), which develops radiopharmaceuticals for oncology centers, the current value of 0.42 reflects a premium over net assets, allowing the market capitalization-to-book value ratio to assess the extent of the overpayment for the company's intellectual potential relative to its tangible asset base.